In Brief
Refine Search
Biotechnology
Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea. 28 November 2024
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Pharmaceutical
Privately-held Swiss company Ferring Pharmaceuticals and its subsidiary Rebiotix look set to achieve a notable first for the industry. 23 September 2022
Pharmaceutical
The UK Chancellor of the Exchequer today announced at the mini-Budget the Long-Term Investment for Technology & Science (LIFTS) competition. 23 September 2022
Biotechnology
A deeper look at late-stage research conducted by Biogen suggests a more positive outlook for its amyotrophic lateral sclerosis (ALS) candidate tofersen. 23 September 2022
Biotechnology
US biopharma Spectrum Pharmaceuticals was 16% down during pre-market trading on Friday, exacerbating Tuesday’s 37% decline. 23 September 2022
Biotechnology
Despite trying to put a positive spin on another regulatory setback for French biopharma company DBV Technologies’ peanut allergy candidate, battered investors sent the firm’s stock down 12% to less than $2 in pre-market trading. 23 September 2022
Biotechnology
Inventiva, which is making solid progress with its candidate for the highly challenging non-alcoholic steatohepatitis (NASH) indication, saw its shares shoot up more than 25% to 5.06 euros yesterday, after the French biotech announced a lucrative licensing deal for its drug lanifibranor in China. 23 September 2022
Pharmaceutical
UK-based GSK’s latest deal has defied the long-term trend among big pharma companies to move investment away from the high-risk, low returns antibiotic space. 22 September 2022
Biotechnology
An Expert View from Georgi Makin, Editor, Phacilitate. 22 September 2022
Pharmaceutical
As with any big pharma company, Swiss giant Novartis periodically holds events to inform shareholders and other interested parties on its updated strategy and optimism for future drug sales. 22 September 2022
Generics
There was positive news from US pharma giant Merck & Co this morning, with respect to patent litigation relating to its blockbuster diabetes drug franchise. 22 September 2022
Biotechnology
Shares of US pharma major Eli Lilly edged up 1.4% to $300.68 pre-market today, on the news that its RET kinase inhibitor Retevmo (selpercatinib) had received a second approval in the USA. 22 September 2022
Biotechnology
Investors are jittery after the sudden departure of French drugmaker Servier from a collaboration in oncology with San Francisco’s Allogene Therapeutics. 22 September 2022
Pharmaceutical
More data from Novo Nordisk’s ONWARDS program show positive results for the firm’s new once-weekly insulin product, insulin icodec. 22 September 2022
Biotechnology
Shares of US biotech Sesen Bio (Nasdaq: SESN) tumbled nearly 33% to $0.45 by close of trading yesterday, after it revealed a plan to merge with privately-held Carisma Therapeutics. 22 September 2022
Pharmaceutical
USA-based Adamis Pharmaceuticals saw its shares plunge as much as 42% yesterday, after releasing disappoint trial results of its COVID-19 treatment candidate. 22 September 2022
Biotechnology
Coeptis Therapeutics has raided the nearby University of Pittsburgh in the latest step towards realizing the company’s aim of disrupting conventional treatment paradigms. 21 September 2022
Biotechnology
A drug candidate that Japan’s largest drugmaker Takeda Pharmaceutical pretty much decided to discontinue back in 2015, has now been out-licensed in a deal that could earn the firm nearly $300 million should it prove successful, albeit with a modest upfront payment. 21 September 2022
Pharmaceutical
Drug pricing policy changes in the USA were signed into law as part of the Inflation Reduction Act last month in one of the most impactful acts of the Biden administration so far. 21 September 2022
Biotechnology
Aiming to delve further into the use of poly ADP-ribose polymerase inhibitor, German life sciences major Merck KGaA has linked up with a leading Italian oncology discovery organization. 21 September 2022
Biotechnology
Shares in US biopharma Spectrum Pharmaceuticals dropped by a massive 37% on Tuesday while those in Swedish biotech Oncopeptides closed 25% lower. 21 September 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze